跳至主要内容
临床试验/NCT02607839
NCT02607839已完成2 期

Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans

University Health Network, Toronto2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2013年2月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
10
试验地点
2
主要终点
Production of TRL-apoB48 between treatments

研究概览

简要总结

The purpose of study is to examine whether raised blood glucose enhances lipid particle production independent of effects on gastric emptying and pancreatic/ gastrointestinal hormone production.

详细描述

This study will be performed on healthy, lean, non-diabetic males and females who will participate two studies each in random order, 4 to 6 weeks apart. Study A: lipoprotein turnover with intravenous infusion of normal saline. Study B: lipoprotein turnover i.v infusion of glucose. In both studies, subjects will drink a liquid formula every hour to remain in a constant fed state and will be under conditions of pancreatic clamp (with the infusion of hormones somatostatin, insulin, glucagon, growth hormone). Subjects will be blinded with regard to the treatments.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women, aged 18 to 60 years
  • Body mass index 20 kg/m2 to 27 kg/m2
  • Hemoglobin above 130g/L
  • Normal glucose tolerance in response to a 75g, 2-hr OGTT

排除标准

  • Subject has a history of hepatitis/hepatic disease that has been active within the previous two years.
  • Any subject with active bleeding, bleeding diathesis, clotting abnormalities or recent surgery (within past 1 month)
  • Any significant active (over the past 12 months) disease of the gastrointestinal, pulmonary, neurological, renal (Cr > 1.5 mg/dL), genitourinary, hematological systems, or has severe uncontrolled treated or untreated hypertension (sitting diastolic BP > 100 or systolic > 180).
  • History of diabetes or OGTT indicative of diabetes or impaired glucose tolerance.
  • Any history of a MI or clinically significant, active, cardiovascular history including a history of arrhythmia's or conduction delays on ECG, unstable angina, or decompensated heart failure.
  • Any laboratory values: AST > 2x ULN; ALT > 2x ULN TSH > 6 mU/l
  • Current addiction to alcohol or substances of abuse as determined by the investigator.
  • Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation
  • Taking any prescription or non-prescription medications at the time of the study
  • Having donated blood three months prior to and three months post study procedures
  • A pregnancy test will be performed 1 to 3 days prior to each study in all female subjects. Those who test positive for pregnancy will be excluded.
  • Known allergy, hypersensitivity or contraindication to receiving study medications.

结局指标

主要结局

Production of TRL-apoB48 between treatments

时间窗: 10 hours

次要结局

  • Production of TRL-apoB100 between treatments(10 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gary Lewis

Professor

University Health Network, Toronto

研究点 (2)

Loading locations...

相似试验